ContraFect Corporation

The momentum for this stock is not very good. ContraFect Corporation is not very popular among insiders. ContraFect Corporation is a mediocre stock to choose.
Log in to see more information.
ContraFect Corp. engages in discovering and developing therapeutic protein and antibody products for...
CFRX Fundamental Data by TradingView

News

ContraFect files for stock and warrants offering to raise $15M
ContraFect files for stock and warrants offering to raise $15M

Seeking Alpha - Healthcare ContraFect files for stock and warrants offering to raise $15M...\n more…

ContraFect files for stock and warrants offering to raise $15M
ContraFect files for stock and warrants offering to raise $15M

Seeking Alpha - Healthcare ContraFect files for stock and warrants offering to raise $15M...\n more…

ContraFect files to sell $15M of common stock, Class E warrants
ContraFect files to sell $15M of common stock, Class E warrants

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

ContraFect files to sell $15M of common stock, Class E warrants
ContraFect files to sell $15M of common stock, Class E warrants

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

ContraFect files to sell 7.03M shares of common stock for holders
ContraFect files to sell 7.03M shares of common stock for holders

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Why Is ContraFect (CFRX) Stock Up 23% Today?
Why Is ContraFect (CFRX) Stock Up 23% Today?

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nContraFect stock is on the move Monday with heavy trading of CFRX as investors react to the latest clinical trial update from the...\n more…